| Date | Title | | | 05/15/12 | Celldex Therapeutics Added to Nasdaq Biotechnology Index| NEEDHAM, Mass.--(BUSINESS WIRE)--May. 15, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the Company will be added to the NASDAQ Biotechnology Index® (NBI), effective prior to market open on Monday, May 21, 2012. The NBI includes biotechnology or pharmaceutical companies listed exclusively on the NASDAQ Global Select Market or on the NASDAQ Global Market that meet predetermined eligibility requirements, including a minimum market capitalization of $200 million and an avera... |
|  | | 05/03/12 | Celldex Reports First Quarter 2012 Financial Results| NEEDHAM, Mass.--(BUSINESS WIRE)--May. 3, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today reported financial results for the first quarter ended March 31, 2012. Celldex reported a net loss of $13.5 million, or $0.27 per share, for the first quarter of 2012 compared to a net loss of $10.1 million, or $0.31 per share, for the first quarter of 2011. At March 31, 2012, Celldex reported cash, cash equivalents and marketable securities of $92.1 million, which the Company believes will be suffici... |
| | | 05/01/12 | Celldex Announces Plans to Release Topline Results from the EMERGE Study in Advanced Breast Cancer| Webcast scheduled for May 23
NEEDHAM, Mass.--(BUSINESS WIRE)--May. 1, 2012-- Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that interim, topline results of the Phase 2b EMERGE study of CDX-011 in patients with advanced breast cancer will be presented in a webcast on May 23, 2012. Linda Vahdat, MD, Professor of Medicine, Chief of Solid Tumor Service and Director of the Breast Cancer Research Program at Weill Cornell Medical College and the lead investigator of the EMERGE study, will... |
| | | 03/14/12 | Celldex Announces Exercise of Over-Allotment Option| NEEDHAM, Mass.--(BUSINESS WIRE)--Mar. 14, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their overallotment option to purchase an additional 1,575,000 shares of common stock at the public offering price of $3.85 per share, less underwriting discounts and commissions. Proceeds from the exercise of the option will be approximately $5.7 million, after deducting underwriting di... |
| |
|
